Дисертації з теми "Vaccine schedule and formulation"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-21 дисертацій для дослідження на тему "Vaccine schedule and formulation".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Alsalih, Dina A. "The Impact of Vaccination Schedules on Infants' and Children's Physio-Psychological Health: A Qualitative Investigation." ScholarWorks, 2014. https://scholarworks.waldenu.edu/dissertations/112.
Повний текст джерелаO'Dwyer, Cliona Anne. "Expression and vaccine formulation of heterologous antigens using commensal Neisseria." Thesis, Imperial College London, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.401669.
Повний текст джерелаAjmera, Ankur [Verfasser]. "Stable spray dried protein formulation and implementation in vaccine development / Ankur Ajmera." Kiel : Universitätsbibliothek Kiel, 2014. http://d-nb.info/1064906036/34.
Повний текст джерелаKaur, Randip. "Liposomes : Formulation and characterisation as contrast agents and as vaccine delivery systems." Thesis, Aston University, 2011. http://publications.aston.ac.uk/15820/.
Повний текст джерелаRyan, Chelsea N., Kathryn L. Duvall, Emily C. Weyant, Kiana R. Johnson, and David L. Wood. "Human Papillomavirus Vaccine Uptake, Knowledge, and Acceptance for Youth: A Systematic Review of Appalachia." Digital Commons @ East Tennessee State University, 2018. https://dc.etsu.edu/asrf/2018/schedule/15.
Повний текст джерелаGarner, Chris, Patricia Conner, and Amanda Stoltz. "Improving Male Vaccine Uptake for Human Papilloma Virus in a Family Medicine Residency Program." Digital Commons @ East Tennessee State University, 2018. https://dc.etsu.edu/asrf/2018/schedule/105.
Повний текст джерелаChu, Leonard Yi. "Dissolving microneedles for cutaneous drug and vaccine delivery." Diss., Georgia Institute of Technology, 2009. http://hdl.handle.net/1853/37177.
Повний текст джерелаKirby, Daniel J. "Formulation and characterisation of an effective particulate delivery vehicle for the novel sub-unit vaccine antigen, Ag85B-ESAT-6." Thesis, Aston University, 2007. http://publications.aston.ac.uk/11065/.
Повний текст джерелаSmith, Jeffrey D. "Vaccination of BALB/c Mice with an Alhydrogel Adjuvanted Whole Cell Trichomonas vaginalis Formulation." Thèse, Université d'Ottawa / University of Ottawa, 2014. http://hdl.handle.net/10393/30424.
Повний текст джерелаGauriat, Marie-Anne. "Connaissance des facteurs déterminants dans la conduite d'un procédé pour la production de toxine par Corynebacterium diphteriae utilisée dans la formulation de vaccins." Thesis, Toulouse, INSA, 2012. http://www.theses.fr/2012ISAT0041/document.
Повний текст джерелаFaced with an important variability in production yields of vaccines against diphtheria, a dynamic systemic approach, including central and iron metabolism and transcriptome analysis, led to an improved knowledge of Corynebacterium diphtheriae physiology, notably as regards the connection of central metabolism and virulence. Gene expression analysis coupled to metabolic characterization enabled a correlation between maltose consumption and virulence to be established. Because of the typical human diet, maltose is present in the human oropharynx where it may serve as a key nutrient source for C. diphtheriae. Maltose consumption during stationary phase, coupled with toxin production, seems to be linked to maintenance and secondary metabolites rather than growth. Several genes, including uptake and catabolism of maltose, are related to diphtheria toxin production. However, mechanisms of regulation are complex and may involve several transcriptional regulators. Bacterial iron requirements and its relation to pathogenicity were considered. Indeed, diphtheria toxin gene is regulated by Fe2+ activated DtxR. These studies revealed that C. diphtheriae is able to store an important quantity of intracellular iron within ferritin-like proteins visualized by NanoSIMS microscopy and the definition of an intracellular threshold concentration provoking expression of toxin production. Finally, genome-wide gene expression analysis of C.diphtheriae in iron starvation and iron excess conditions provided information on relations between central and iron metabolism, virulence establishment and oxidative stress. The resulting knowledge was exploited to suggest process optimization strategies to enhance toxin production, currently being assessed by the industrial partner. Adjusting some key physico-chemical parameters (targeting oxygenation and better maltose metabolization) enabled significant gains in toxin production (2.5 fold increase). Specific productivity could be increased by 2.2 thanks to a novel biomass dilution and recycling step at the end of the culture
Coolen, Anne-Line. "Formulation et vectorisation d’un ARN messager vaccinal codant l’antigène Gag du VIH-1 à l’aide de nanoparticules biodégradables de poly(acide lactique)." Thesis, Lyon, 2018. http://www.theses.fr/2018LYSE1292.
Повний текст джерелаMRNA-based vaccines currently raise a growing interest in vaccinology. However, the transport and delivery of mRNAs to DC cytoplasm in order to induce antigen production and immune responses remains challenging. The objective of this thesis concerns the design and evaluation of novel strategies to vectorize vaccine mRNAs by poly(lactic acid) nanoparticles (PLA-NPs). We developed a strategy based on mRNA adsorption onto PLA-NPs using, as intermediate, LAH4-L1, an amphipathic cationic peptide. To do this, mRNAs were condensed by LAH4-L1 to form polyplexes which was then adsorbed onto PLA-NPs in a second step to form nanocomplexes. The LAH4-L1/mRNA polyplexes and PLA-NP/LAH4-L1/mRNA nanocomplexes ability to target DCs and induce immune responses in vitro was evaluated. We showed that formulations induce an efficient transfection of mRNA in DCs in vitro. The addition of PLA-NPs in formulations seems to increase sustained expression of mRNAs. DC treatment by inhibitors revealed that polyplexes and nanocomplexes are taken up by phagocytosis and clathrin-dependent endocytosis, and escape endosomes by a v-ATPase-dependent mechanism. Transfection of monocyte-derived DCs (moDCs) showed that LAH4-L1/mRNA polyplexes and PLA-NP/LAH4-L1/mRNA nanocomplexes trigger innate-sensing activation with pro-inflammatory responses. This activation is associated with moDCs maturation, MHC-I and MHC-II presentation, and the secretion cytokines and chemokines involved in adaptive immunity.These data highlight the interest of these new platform formulations to vectorize mRNAs, target DCs and induce immune responses, which in the context of HIV-1, could help the immune system to control the viral load
Kakhi, Zahra. "Conception de constructions liposomiques destinées à la vaccination antitumorale par voie respiratoire." Thesis, Strasbourg, 2014. http://www.theses.fr/2014STRAF044/document.
Повний текст джерелаWith the identification of tumor antigens and the better understanding of the mucosal immune response, the vaccination by the respiratory route has become a promising field of investigation for cancer treatment. The purpose of this study was to develop nanoparticulate peptide-based liposomal vaccines for antitumor vaccination by respiratory or nasal route. Thus, we have prepared liposomes associating ErbB2 TCD8+ and HA TCD4+ peptide epitopes with an adjuvant molecule. This construct was then optimized by varying its physicochemical characteristics (size, structure, composition) or its formulation (viscosity). The antitumor efficacy of the various vaccines obtained thereby was evaluated in a model of pulmonary or subcutaneous tumors in mice after prophylactic or therapeutic, nasal or respiratory immunization. All our data showed an undeniable interest of peptide vaccines based on liposomes in the antitumor vaccination by the respiratory and nasal routes, opening new perspectives for cancer treatment
Rogers, Carley. "Using Mathematical Modelling to Evaluate Human Papillomavirus Vaccination Programs in Canada." Thèse, Université d'Ottawa / University of Ottawa, 2013. http://hdl.handle.net/10393/26228.
Повний текст джерелаBahuaud, Mathilde. "Vaccination anti-pneumococcique chez les sujets à risque d'infections invasives à pneumocoques et prévention de l'hyporéponse Immunogenicity and persistence of the 13-valent pneumococcal conjugate vaccine (PCV13) in patients with untreated smoldering multiple myeloma (SMM): a pilot study Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study Prevention of hyporesponsiveness by modulation of schedule and doses of pneumococcal vaccine immunization." Thesis, Sorbonne Paris Cité, 2018. http://www.theses.fr/2018USPCB067.
Повний текст джерелаTwo vaccines are currently available for the prevention of invasive pneumococcal diseases (IPD): a polysaccharide vaccine, Pneumovax® (PPV23) and a conjugate vaccine, Prevenar13® (PCV13), inducing protection against 23 and 13 serotypes, respectively. PPV23 is considered to be weakly immunogenic, particularly in the elderly and immunocompromised patients. PCV13, however, due to the conjugation to a carrier protein, has the advantage of inducing a T-dependent immune response, not observed with PPV23 vaccine. In our work, we therefore evaluated the impact of vaccine strategies using PCV13 and PPV23 on different populations of patients at risk of IPD. In a first study, our results on anti-pneumococcal vaccination in patients with smoldering myeloma (SMM) showed that a single dose of PCV13 induces a transient immune response and long term persistence. These results suggested the use of a vaccination schedule including several doses of PCV13 or association with the PPV23. Since 2013, this combined strategy of PCV13 and PPV23 is recommended by la Haute Autorité de Santé (HAS) for patients at risk, with the following delays: a dose of PCV13 followed by a dose of PPV23, 8 weeks later. We then studied this combined vaccine strategy in patients at risk of IPD: patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Our results show a short-term immunogenicity of the combined strategy, but a protection that does not persist beyond two years. Surprisingly, antibody levels 2 years after vaccination are lower than pre-vaccine levels for RA patients. This negative effect of PPV23 on PCV13-induced immune response is called hyporesponsiveness. This phenomenon, observed in RA patients, is not found in SLE patients who received PPV23 vaccination at distance from PCV13. These results suggest that the delayed vaccination schedule (ie, PPV23 vaccination six months after PCV13 instead of two months) could inhibit the hyporesponsiveness phenomenon. In a third study, we compared different vaccine strategies modulating vaccine doses and injection times in healthy volunteers but also in a mouse model of hyporesponsiveness developed in our laboratory. Our hypothesis was that modulation of the vaccine schedule using both vaccines could both induce long-term protection and prevent hyporesponsiveness. Our results showed that decreased doses of PPV23 or concomitant injection of both vaccines did not prevent hyporesponsiveness. However, by increasing the delay between PCV13 and PPV23, the phenomenon of hyporesponsiveness is limited. Clinical studies in patients at risk of IPD are needed to evaluate a delayed combined strategy, where PPV23 would be received at least 6 to 12 months after PCV13
Gill, Harvinder Singh. "Coated microneedles and microdermabrasion for transdermal delivery." Diss., Atlanta, Ga. : Georgia Institute of Technology, 2007. http://hdl.handle.net/1853/24711.
Повний текст джерелаCommittee Chair: Dr. Mark R. Prausnitz; Committee Co-Chair: Dr. Mark Feinberg; Committee Member: Dr. Mark Allen; Committee Member: Dr. Niren Murthy; Committee Member: Dr. Peter Hesketh; Committee Member: Dr. Robert Swerlick
Johnson, Meredith. "Motivational interviewing for vaccine hesitant parents." Thesis, 2017. https://hdl.handle.net/2144/26708.
Повний текст джерелаJesus, Sandra Cristina Campos de. "Adjuvant Nanocarriers for Hepatitis B Vaccine: Formulation Design and Mechanistic Studies." Doctoral thesis, 2016. http://hdl.handle.net/10316/29568.
Повний текст джерелаA vacinação tem um papel essencial na área da saúde pública e um enorme impacto na sociedade moderna. O desenvolvimento de formulações mais seguras tem levado a que a investigação de vacinas baseadas em microorganismos vivos inativados ou mortos seja preterida em prol da utilização de pequenas proteínas ou de outras moléculas contendo epítopos antigénicos, cuja imunogenicidade é reduzida. Contudo, o sucesso dessas vacinas depende da presença de adjuvantes imunológicos, por forma a aumentar a resposta imune gerada. Ao longo dos últimos anos diversas nanoparticulas (NPs) políméricas têm sido estudadas como sistemas adjuvantes de vacinas, funcionando como sistemas de entrega, protegendo os antigénios e aumentando o reconhecimento e internalização destes por parte de células especializadas do sistema imunológico. Face ao exposto, o objetivo do trabalho subjacente à presente dissertação consistiu na preparação e avaliação de NPs poliméricas de poli-caprolactona (PCL) e quitosano como adjuvantes de uma vacina para a hepatite B. As NPs preparadas através do método de nanoprecipitação foram pormenorizadamente caracterizadas e as suas capacidades como adjuvantes avaliadas através de ensaios in vitro e in vivo. Quando suspensas em água, as NPs apresentaram um tamanho aproximado de 200 nm e um potencial zeta positivo (+ 25 mV). Estas NPs, constituídas pela mistura física dos dois polímeros, revelaram citocompatibilidade com diversas linhas celulares e células primárias, boa interação e internalização celular. A presença de quitosano na superfície das NPs maioritariamente constituídas por PCL, permitiu obter partículas com uma elevada capacidade de carregamento de proteínas modelo e de plasmídeos através de adsorção à superfície. Usando células mononucleares isoladas a partir de sangue periférico humano, demonstrou-se que estas NPs não induzem a secreção do fator de necrose tumoral alfa (TNF-), uma citocina ligada a reações inflamatórias, que, por vezes, está também na base do mecanismo de ação de alguns adjuvantes. Por outro lado, descobriu-se que as NPs de PCL/quitosano são ativadoras de mastócitos. A ativação destas células leva à sua desgranulação, favorecendo a libertação de mediadores imunológicos que tem um papel activo na geração da resposta imune. Ambas as descobertas foram importantes contribuições sobre o mecanismo adjuvante das NPs de PCL/quitosano. Neste trabalho, estudos de vacinação de murganhos C57BL/6 permitiram validar, pela primeira vez, a aplicação das NPs de PCL/quitosano como um sistema adjuvante na vacinação contra a infeção pelo vírus da hepatite B. Inicialmente, testou-se uma vacina de ADN, na qual o plasmídeo codificado para a expressão do antigénio de superfície do vírus da hepatite B (HBsAg) foi adsorvido à superfície das NPs. No entanto, a resposta imune obtida com esta abordagem foi negligível. Por sua vez, asformulações desenvolvidas com a proteína recombinante HBsAg adsorvida à superfície das NPs levaram a uma forte resposta humoral quando administradas pela via subcutânea, superior à resposta gerada pela vacinação com a vacina comercial Engerix-B®, na mesma dose. A reposta gerada foi dependente da dose de NPs administrada, sendo que doses mais elevadas deste adjuvante nanoparticulado geraram um aumento estatísticamente significativo na produção de citocinas secretadas por linfócitos do tipo Th1 e Th17. Numa outra abordagem, foram ainda usados exosomas, adjuvantes imunológicos ainda pouco explorados para vacinas baseadas em proteínas recombinantes, mas cujas propriedades têm revelado vantagens em estratégias de vacinação contra tumores. Os resultados da vacinação subcutânea com exosomas como adjuvantes da formulação de NPs adsorvida com o HBsAg, demonstraram o aumento da resposta imune inata in vivo, ilustrada pelos níveis basais elevados de interferão gama (IFN-) secretado por esplenócitos. No entanto, a utilização desta formulação não se mostrou vantajosa na resposta imune específica. Por fim, realizaram-se estudos de vacinação pela via nasal encorajados pelos bons resultados da vacinação subcutânea e pela capacidade que as NPs demonstraram de adsorverem mucina, uma glicoproteína abundante no muco e de ficarem retidas sobre uma camada artificial de muco produzida in vitro. Estes estudos mostraram a possibilidade da utilização das NPs de PCL/quitosano para vacinação nasal contra a hepatite B, utilizando quantidades muito reduzidas de antigénio. Em suma, ao longo dos trabalhos realizados no âmbito da presente tese de doutoramento, foi possível caracterizar e testar com sucesso as NPs de PCL/quitosano como adjuvantes da vacinação, quer pelo efeito de transporte, quer pelo efeito imunoestimulante. Apesar da extrapolação dos resultados entre antigénios recombinantes apresentar limitações, as conclusões inferidas ao longo dos estudos são de grande importância para futuras aplicações deste sistema polimérico.
Vaccination is a major achievement in global public health, with a huge impact on modern society. The development of safer formulations has instigated the use of small proteins and other molecules containing antigenic epitopes instead of the inactivated or killed microorganisms. Those antigens have reduced immunogenicity and their efficacy is dependent on the presence of immunological adjuvants. Over the last years, different polymeric nanoparticles (NPs) have been tested as vaccine adjuvants acting as delivery systems, which protect and enhance the recognition of the antigen and its internalization by the specialized immune system cells. Given the aforementioned considerations, the studies underlying the present dissertation aimed at preparing and evaluating polymeric NPs, based on poly-caprolactone (PCL) and chitosan, as adjuvants for hepatitis B vaccine. PCL/chitosan NPs, prepared by a nanoprecipitation technique, were characterized and their capabilities as a vaccine adjuvant tested through in vitro and in vivo assays. When suspended in water, NPs measured approximately 200 nm and presented a positive zeta potential (+ 25 mV). These NPs, constituted by the physical blend of two polymers, demonstrated to be cytocompatible with various cell lines and primary cells and revealed a good cellular interaction and internalization. The presence of chitosan on the surface of the NPs mainly constituted by PCL, yielded particles with a high loading capacity for model proteins and DNA plasmids through surface adsorption. Using mononuclear cells isolated from human peripheral blood, it was possible to demonstrate that PCL/chitosan NPs did not induce TNF- secretion, a cytokine linked to inflammatory response and sometimes related to adjuvants mechanism of action. On the other hand, it was observed that PCL/chitosan NPs are mast cell activators. By inducing the activation, NPs contribute to mast cell degranulation, favoring the release of immune mediators with an active role in the generation of a protective immune response. These discoveries are important contributions to the knowledge of the PCL/chitosan NPs adjuvant mechanism. Vaccination studies were performed in C57BL/6 mice, allowing for the first time, the validation of PCL/chitosan NPs as an adjuvant for a vaccine against hepatitis B virus. One of the approaches considered was the development of a DNA vaccine, in which a plasmid encoding for the hepatitis B surface antigen (HBsAg) recombinant protein was adsorbed on the surface of the PCL/chitosan NPs. However, this approach conducted to a negligible immune response. On the other hand, a formulation developed with the recombinant HBsAg protein adsorbed on NPs surface led to a strong humoral immune response when administered subcutaneously, superior to the response generated by vaccination with the commercial vaccine Engerix-B®, at the same dose. It was also found that the response generated was dependent on the NPs dose since highest doses of the adjuvant caused a significant increase in the production of cytokines secreted by Th1 and Th17 lymphocytes. In another strategy, exosomes were used as co-adjuvants of the nanoparticulate formulation vaccine. In the literature, exosomes are described as effective immunological adjuvants for tumor vaccination strategies but they are not yet widely explored as vaccine adjuvants for recombinant antigens. The study developed in this thesis demonstrated an increase in mice innate immune response after subcutaneous vaccination with the formulation co-adjuvanted with exosomes, as illustrated by the high production of basal IFN-from splenocytes. However, this formulation showed no advantage in the specific immune response. Finally, vaccination studies through the nasal route were developed, encouraged by the good results of the subcutaneous immunization, together with the results demonstrating the ability of this NPs to adsorb mucin, an abundant glycoprotein in the mucus, and to be retained in an artificial mucus layer produced in vitro. The results showed the possibility of using PCL/chitosan NPs for nasal vaccination against hepatitis B using very small amounts of antigen. Overall, with the work herein developed and described, it was possible to characterize PCL/chitosan NPs and test their ability as a delivery system and immunostimulatory adjuvant for vaccination purposes. Despite the extrapolation of these results to other recombinant antigens presents some limitations, the conclusions drawn here are of great importance for future applications of PCL/chitosan NPs.
FCT - SFRH/BD/81350/2011
Li, Xinran. "Vaccine formulation development : towards addressing major limitations of vaccines that are adjuvanted with aluminum salts." Thesis, 2013. http://hdl.handle.net/2152/28737.
Повний текст джерелаtext
Machado, Fátima Alexandra Meira. "Development of a liposomal formulation for peptide delivery to serve as vaccine against chronic myeloid leukemia." Master's thesis, 2013. http://hdl.handle.net/1822/29422.
Повний текст джерелаThe main goal of this work was to characterize and explore the potential of Dioctadecyldimethylammonium Chloride (DODAC) / Monoolein (MO) liposomes in a 1:2 proportion and identify the formulations that could be used in the development of an immunoprotective protocol for Chronic Myeloid Leukemia (CML). CML has long been recognized as one of the most responsive leukemic disorder to immunotherapy. CML is potent model for immune therapy in humans because there is a specific gene rearrangement, BCR/ABL, which product, P210bcr/abl, can be the target antigen. The loading of drugs into particles at the nanometer size range is a recognized technique for the optimization of controlled drug delivery. In its use in vaccines, liposomes have the advantage of being able to maintain antigens present in the organism for long enough to obtain an immune response. Different methods of preparation and distinct peptide/lipid molar ratios were used to prepare P210bcr/abl / DODAC:MO (1:2) nanoparticles. This thesis describes results for biophysical characterization of the peptide/lipid system, encapsulation efficiency and exposure of THP-1 cells to the nanoparticles. The lipid content was essential to achieve the desired nanoparticles. The highest lipid concentration showed higher encapsulation, however, a lower lipid content induced a more efficient cell response. The peptide/lipid system was capable of inducing a stronger cell response than the peptide by itself, emphasizing the potential of this system in vaccine development for the treatment of CML.
O objetivo principal deste trabalho foi caracterizar e explorar o potencial dos lipossomas de cloreto de Dioctadecildimetilamónio (DODAC) / Monooleina (MO) numa proporção de 1:2 e identificar as formulações que poderão ser usadas no desenvolvimento de um tratamento imunoprotetor para a Leucemia Mieloide Crónica (LMC). A LMC é desde há muito tempo conhecida como uma das desordens imunológicas mais responsivas à imunoterapia. A LMC é um poderoso modelo para imunoterapia em humanos devido à existência de um gene específico BCR/ABL, cujo produto, P210bcr/abl, pode ser usado como antigene-alvo. A incorporação de fármacos em partículas a uma escala nanométrica é uma técnica reconhecida para a optimização da entrega controlada de fármacos. No seu uso em vacinas, os lipossomas possuem a vantagem de ser capazes de manter os antigenes presentes no organismo o tempo suficiente para se obter uma resposta imune. Diferentes métodos de preparação e várias razões molares de péptido/lipido foram usadas para preparar nanoparticulas de P210bcr/abl / DODAC:MO(1:2). Esta tese descreve os resultados obtidos da caracterização biofísica do sistema péptido/lípido, eficiência de encapsulação e exposição das células THP-1 às nanopartículas. O conteúdo lipídico foi essencial para obter nanopartículas desejáveis. A concentração mais alta de lípido demonstrou maior eficiência de encapsulação, no entanto, uma concentração de lipído mais baixa mostrou-se mais eficiente em induzir uma resposta por parte das células. O sistema péptido/lipido foi capaz de induzir uma resposta mais forte do que o pétido por si só, enfatizando o seu potencial no desenvolvimento de uma vacina para o tratamento da LMC.
Choi, Jin Huk. "Modeling pre-existing immunity to adenovirus as a method to identify novel formulations for a protective Ebola vaccine." 2012. http://hdl.handle.net/2152/19602.
Повний текст джерелаtext
Tantituvanont, Angkana. "Novel formulation : development of oral microparticulate non-viral DNA vaccine delivery system against infectious hematopoetic necrosis virus (IHNV) in Rainbow Trout, statistical design in matrix tablets formulation." Thesis, 2003. http://hdl.handle.net/1957/31818.
Повний текст джерелаGraduation date: 2003